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ABSTRACTS 
BACKGROUND: Economic evaluation of health programs primarily captures costs within 
the health care system, but may also capture costs that fall on patients, relatives, other public 
sectors or society in general. Guidelines vary with respect to nomenclature and which costs to 
be included, and systematic reviews of economic evaluation indicate that this variation carries 
over to published analyses. For certain health interventions, such as cervical cancer screening, 
exclusion of non-health-care costs can lead to a biased outcome.  
OBJECTIVES:  The aim of this thesis was first to explore to what extent economic evaluation 
of cervical cancer screening includes non-health-care costs, and second, to study the 
methodological disparities shown in estimation and incorporation of non-health-care costs.  
METHODS: A systematic search of three electronic databases was conducted to identify 
relevant publications on economic evaluation of cervical cancer screening. Included articles 
were reviewed to explore 1) whether non-health-care costs were included, 2) which cost 
components were included, and 3) how they were incorporated into estimation. For those 
studies including non-health-care costs, the magnitude of non-health-care costs compared to 
health care costs were estimated.  
RESULTS: In total, 82 articles were included in the study, and 40 of which included non-
health-care costs which were slightly less than half of studies. The studies varied considerably 
in identification, measurement and valuation of non-health-care costs. Several studies made 
un unclear distinction between time and productivity costs, and showed low adherence to the 
recommendations of guidelines. The included studies showed variations in terms of the 
magnitude of non-health-care costs compared to the health care costs. Travel and time costs 
account for 0.04-76% of the total screening costs, and 5-48% of cancer treatment costs. 
CONCLUSION: Non-health-care costs involved in screening for cervical cancer are not 
insignificant. Therefore, studies which did not consider such costs may have limited 
implications for social resource allocation. Consequently, this study calls for more clear and 
explicit definitions of non-health-care costs, more consistent guidelines and better reporting of 
economic evaluation. 
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1 INTRODUCTION 
Resources consumed in one place cannot be used for other use, so we are often faced a 
prioritization dilemma. In health care, the pressure on health spending becomes greater than 
ever. As recent series of economic turmoil more strains health care budgets while health care 
demand becomes more diversified as ageing society emerges, the amount of resources is too 
limited to meet the growing demands in health care. In this context, the decision makers 
should make a choice among competing health care programs (health interventions) so as to 
maximize effectiveness while requiring less cost.  
As a tool for the appraisal of health program, economic evaluations support their choices by 
providing information to facilitate valid comparison of alternative use of limited resources. 
Drummond defines the economic evaluation as ‘the comparative analysis of alternative 
courses of action in terms of both their costs and consequences’[1]. Since economic 
evaluation was first introduced in 1960s, its publication has been growing along with its 
popularity [2, 3].  Economic evaluation is widely applied in health policy in assessment of 
health programs and its use in decision making also increases [4]. Conducting economic 
evaluation requires researchers to identify, measure and compare all of the significant positive 
and negative costs and consequences of alternative programs of addressing a given problem 
[5].  
In estimation of cost effectiveness of each comparator, all relevant costs and effects needs to 
be estimated  in a comprehensive and valid way [6].  Health care programs not only require 
use of resources within the health care system (“health care costs”), but also entail use of 
patients’ and relatives’ ‘time’ and lost ‘productivity’ (“non-health-care costs”). Which costs 
should be included is one of key analytic decisions to be made. In particular, omission of 
costs outside of health care system has more influence on certain health intervention, for 
example, cervical cancer screening. Cervical screening program have significant implication 
that it requires regular day off for young women who are actively participating in labor 
market. Therefore, time and productivity costs associated with absenteeism and cost savings 
in added life years as a result of preventive effect of screening are known to be significant 
compared to other health interventions. In that, failure to fully capture the relevant costs 
distorts the outcome of studies and lead to suboptimal decisions.  
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Nevertheless, the disagreement between guidelines of economic evaluation in the way of 
determining relevant costs and its measurement has led to confusion. A recent systemic 
review of economic evaluation guidelines finds that there are significant methodological 
disparities in dealing with costs outside of health care sector [7].  Some of these disparities are 
attributed to the misunderstanding of the principles of economic evaluation but different 
opinions on methodological choices are also one of causes [8] . Lack of consensus between 
guidelines gives more choices for decision analysts which subsequently reduce comparability 
and transferability of economic evaluations [1].  Misleading study findings could 
subsequently limit the use of economic evaluation in policy decision making and have 
opportunity costs because of suboptimal decisions. [9]. This is because it is unclear whether 
the difference in research outcomes is attributable to the methods being used or actual 
variation in cost-effectiveness. In order to figure out the question, more information needs to 
be required, but additional economic evaluation is costly. Therefore, researchers need to 
ensure that studies are directed properly and their methodological choice on costing is as 
accurate and valid as possible. Identifying and measuring relevant costs needs careful 
consideration and transparency in a process. 
This study aims to explore to what extent costs outside of health care are considered in 
economic evaluation studies of cervical cancer screening and how they are incorporated into 
the economic evaluations. More detailed study question and methods would be further 
described in the latter part of the study. Basically, this study is composed of five chapters. The 
introduction part deals with the basic concepts of economic evaluations and theoretical 
approaches in defining, and estimating non-health-care costs within existing literatures and 
guidelines. In Chapter 2, the study methods used to analyze current practice of costing non-
health-care costs would be described using a flow chart of a systematic review. Chapter 3 
presents the results of the studies, to what extent the non-health-care costs were considered, 
and how they were identified and measured in economic evaluation. In Chapter 4, the 
discussion related to the results of study would be made. Chapter 5 finally suggests the 
conclusion of the analysis.  
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1.1 Cervical Cancer Screening 
Cervical cancer is one of the most common causes of cancer deaths in developed countries 
and its burden to both society and patients is also substantial [10]. Annually, 530,000 women 
are diagnosed of cervical cancer worldwide, and 270,000 women are died from it, which is 
around 7% of all women cancer deaths [11]. The incidence of cervical cancer peaks at the age 
of 30-40 [12].  Cervical cancer is progressed through 4 stages (I-IV) and its treatment and 
prognosis is dependent on the stage. In a case where cytological abnormalities are suspected 
in the test result, colposcopy and biopsy are performed additionally for confirmation. Women 
who are diagnosed of early stage cancer are treated with surgery. Radiotherapy is used for 
women in more developed stage of cervical cancer. When cervical cancer is progressed to III 
and IV, survival rate decreases to 39% and 15% respectively. 
Conventional Cytology and HPV test 
However, cervical cancer is preventable through detection of cancer precursors [13, 14]. Since 
1960s, the Papanicolaou (Pap) test has played an important role in detecting premalignant 
cytological lesion and resulted in significant drop in incidence and mortality of cervical 
cancer [15]. For countries where health resources and number of trained personnel are limited, 
visual inspection with acetic acid (VIA) can be an alternative screening method [16] in that 
the VIA is relatively easy and simple method using 3-5% of acetic acid for observing 
dysplastic epithelium with unaided eye [17].  
In the 1980s, infection of certain human papillomavirus (HPV) types was identified as the 
cause of cervical cancer [8, 9]. HPV is sexually transmitted infection, and 50-80% of women 
who are sexually active are exposed to HPV once in a life time. Persistent infection of 
carcinogenic HPV type is a necessary condition of high grade cervical intraepithelial 
neoplasia (CIN) which can progress to invasive cervical cancer. In particular, high-risk HPV 
types 16 and 18 have been identified as being present in approximately 70% of cervical 
cancers [18].  
HPV DNA tests have much higher sensitivity compared to the Pap test, which allows 
detection of more precursors of cervical cancer in early stage [19]. Because the early detection 
of precancerous lesions reduces frequency of screening, the HPV DNA test is expected to 
reduce the additional visits for testing as well as costs of cancer treatment. HPV DNA is 
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usually detected via cervical and vaginal samples, and these samples can be collected by 
women themselves. Use of self-collected vaginal specimens can additionally reduce the costs 
of pelvic evaluation with increasing women’s compliance to the screening [20, 21].  
Economic evaluation of cervical cancer screening  
During the last 40 years, a range of cost effectiveness analyses of cervical screening have 
been published; this research trend is followed by developing countries where introduction of 
national screening program is concerned. In the 1980s it was detected that cervical cancer is 
caused by the HPV, which led to growing interests in HPV test and HPV vaccination. Since 
then, a number of economic evaluations have been published to estimate the feasibility of 
introducing HPV DNA testing to replace or supplement current Pap test. Because these new 
technologies bring additional costs, the number of cost effectiveness studies to compare HPV 
DNA test and existing cytology is increased. The main issue of recent economic evaluations 
is whether cost savings in high sensitivity of HPV DNA test is able to offset the added cost. 
After HPV vaccination was found to be effective to prevent HPV infection primarily, 
combination of HPV vaccine and regular screening has been also studied. 
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1.2 Types of Economic Evaluations 
In a broad term, economic evaluation includes Cost-Effectiveness Analysis (CEA), Cost-
Utility Analysis (CUA), Cost-Benefit Analysis (CBA), Cost-Minimization Analysis (CMA), 
Cost Consequence Analysis (CCA), and Cost of Illness Study (COI).  But, full economic 
evaluation requires 1) comparison of alternative health programs and 2) costs and 
consequences of each health program [1]. In this sense, the study types which fulfill full 
requirements of economic evaluation are Cost-Effectiveness Analysis (CEA), Cost-Utility 
Analysis (CUA) and Cost-Benefit Analysis (CBA).  
Table 1. Unit of cost and effect of economic evaluation 
    Unit of Cost Unit of Effect  
Cost-Effectiveness Analysis  
(CEA) 
Monetary term A natural unit                          
(life-years gained, symptom free 
day, case detected, etc.) 
Cost-Utility Analysis 
(CUA) 
Monetary term Quality Adjusted Life Years 
(QALY) 
Cost-Benefit Analysis 
(CBA) 
Monetary term Monetary value 
 
CBA is more distinctive form of study in that the valuation of all outcomes of CBA, both 
costs and consequences, are measured in monetary terms. On the contrary, CUA and CEA are 
considered more similar types of study [22, 23] since those two are nearly common in dealing 
with costs and effects and comparing health programs in terms of their cost per unit of effect 
[1]. The only difference between them is a unit of measuring effects. In measurement of 
effects of health program, CEA uses natural units such as saved life years, number of 
symptom free days or number of incidents averted. These units are program specific and it 
accords with the aim of CEA that makes best choice to maximize health benefits. The 
consequence of CUA is presented in terms of preference based measures of health, named 
Quality Adjustment Life Years (QALY). QALY has advantages over natural units in that it 
combines time and its utility into a single unit which enables comparison between health 
programs with different outcomes available. In consideration of the similarities between CEA 
and CUA, some authors uses the term ‘CEA with QALYs’ and include CUA under the CEA  
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[23, 24]. However, this study maintains the use of the term CUA for further controversy over 
productivity costs and its reflection on QALYs.  
On the other hand, Cost Minimization Analysis (CMA) and Cost of Illness (COI) study are 
partial economic evaluations since their interests focus more on costs. The application of 
CMA is limited to the case when the outcomes of alternative health programs are similar so 
that only cost difference is a subject of interest. COI is used to study economic burden of 
disease, and thus only involves costs of disease. Cost Consequence Study (CCS) presents its 
outcome in disaggregated form instead of combining different components of competing 
health programs in order that users make judgment based on trade- offs between different 
types of costs and effects.  
1.2.1 CEA  
Cost Effectiveness Analysis (CEA) presents its results as an incremental ratio of additional 
costs to additional effects for one health program compared with another [25]. For choice of 
competing programs, costs effectiveness ratio (C/E ratio) of each program is ranked from the 
lowest to the highest. From the program with the lowest C/E ratio is selected until all 
resources are spent or society does not have willingness to pay for the program anymore. 
Since C/E ratio does not function itself as a standard to make a choice of appropriate program, 
a ‘threshold C/E ratio’ is used to assess whether a program is worth being conducted [1].  The 
threshold is “upper level for accepted cost effectiveness” [26]  and mostly reflects societal 
willingness to pay. On C/E ratio, costs are placed on the numerator while effects are on the 
denominator. The table below is extracted from the estimation of Drummond [1]. This table 
identifies costs and savings based on the place where they aroused from.  
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Figure 1. Costs and consequences of economic evaluation 
 
 
 
Costs (C) or savings (S) for the intervention occurred in  
C1∕ S1: in organizing and operating the health intervention 
C2∕ S2: voluntary or public agencies 
C3∕ S3: out-of-pocket money, traveling expenses, expenditures in home, time for seeking and 
receiving treatment  
C4∕ S4:  productivity changes for the treatment, morbidity and mortality 
 
In CEA, possible formulations of economic evaluation can be expressed in two ways as below: 
(C1 – S1)/E 
[(C1+C2+C3+C4)-(S1+S2+S3+S4)]/E 
The numerator is the sum of resources consumed and saved. The resources saved are the costs 
not spent in the alternative program. The denominator is the effects of health care intervention. 
The formal formula is only concerned with costs and effectiveness in health care sector while 
the latter is from the societal perspective which takes into account resources consumed in 
other sectors as well as costs paid by patients themselves.  
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In CEA, all kinds of non-health-care costs including travel cost, time cost and productivity 
costs are recommended to be included in the numerator of the C/E ratio.  
1.2.2 CUA 
Health care intervention is an attempt to extend life both in quality and quantity dimensions 
throughout “improving the health state and/or prolong the duration of life”[26]. In Cost-
Utility Analysis (CUA), effect of health intervention is expressed in terms of QALY. The 
QALY is a single unit of measurement incorporating both quality and quantity of health 
changes as a result of health program. Use of QALY has been growing since its first use in 
1970s [22]. Its use is to help government organizations to make decision so as to maximize 
the value of health expenditures in terms of health outcomes [27].  
As QALY collapse different types of health effects into a single preference based measure, it 
enables to analyze health program with more than one kind of health effects and to compare it 
with other health programs with different types of health effects  [24].  QALY is calculated by 
multiplying a length of life with a quality adjustment weight which is scaled from 0 (dead) to 
1 (perfect health). A year of perfect health is, therefore, assumed to be 1 QALY. Death is 
considered to be 0 QALY. 
QALY= T *Q 
T: time (years)   Q: quality of life 
Quality adjustment weight is based on individual’s preference or relative desirability of the 
health state in question. The measurement of individual preferences is acquired through 
preference measurement tools such as Time Trade- off (TTO), Visual Analogue Scale (VAS), 
or Standard Gamble (SG). Self-rated questionnaires, called “health state descriptive systems” 
or “a generic health state preference instrument” (ex. EQ-5D, 15D or SF 36) assign preference 
scores to different health states. These measurements are composed of multiple dimensions of 
health states and levels of improvements so that it measures a multi-attribute utility that 
reflects individual preference both within and across health dimensions [28].  
Formulations for incorporating costs and consequences to CUA are as below: 
(C1 – S1)/U 
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[(C1+C2+C3+C4)-(S1+S2+S3+S4)]/U 
Costs (C) or savings (S) are same as CEA  
U: QALYs 
Incorporation of C4 (production loss) in CUA is a controversial issue in that some argues that 
QALY captures production loss to individuals when it is measured. This issue is more dealt 
with details in the later part.  
Decision making process of CUA is as same as that of CEA. Outcome of CUA is presented as 
an incremental ratio of additional costs to additional QALY. Program with the least cost per 
QALY is selected in order so as to maximize the utility until the given budget is exhausted.   
1.2.3 CBA 
The most distinctive feature of CBA compared to other economic evaluation is that all effects 
of health intervention are valued in monetary terms. A limitation of CEA and CUA is that 
they only compares cost effectiveness ratio so that they cannot tell whether a health program 
is worthwhile of being conducted. However in CBA, the health costs and outcomes of 
intervention are commensurate so that it can be applied to a wide range of scope. As a result, 
it enables comparison across programs in other sectors of the economy such as transport and 
environment [1].  
CBA identifies whether the program’s benefits are greater than its costs. Therefore, the costs 
and benefits of competing interventions should be examined [29]. A positive net social benefit 
of CBA resulting from direct comparison of benefit and cost indicates that the program is 
worthwhile of being conducted. When several health interventions are considered, the 
combination which maximizes benefits is chosen. Within a fixed budget, decision rule of 
CBA allows resources to be allocated in a program where exceeding benefit is the highest.  
Benefits from a health intervention are gained improvement in health per se and increased 
productive output [1]. However, undesirability and criticism against monetary valuation of 
such benefits have tended to limit the use of CBA [5].  As a proxy to value the benefits of 
health intervention, human capital approach (HC) was introduced by assigning wage rate. 
However, this approach has been criticized due to its lack of theoretical ground and 
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discrimination against people outside of labor market. In this respect, willingness to pay 
approach (contingent valuation) is more welcomed by economists who favor value judgment 
based on individual’s preferences [30]. Individual preferences can be assessed by survey or 
inferred from decisions actually made that involve tradeoffs between health and money [23]. 
Respondents are asked to answer hypothetical scenarios about the health intervention and 
present their maximum value that they are willing to pay for the intervention. In practice, 
there is a limitation that respondents are strongly influenced by the format and wording of 
hypothetical questions [26] . 
1.3 Types of Costs 
Health program requires resources and these resources not only come from health care sector, 
but also from other part of society such as social services, patients and unpaid informal care 
givers. When comparing health care programs requiring resources from different sectors, 
estimating only resources spent in health care sector is not comprehensive. Identification and 
classification of relevant costs is an important process in conducting analyses.  
In terms of cost classification, a dichotomous way of classifying the costs into ‘direct’ and 
‘indirect’ costs has been widely used [23]. However, reluctance to use such classification was 
aroused due to its inconsistent use and lack of standard definition. Direct cost refers to the 
consumed resources in provision of health care program including health services, 
pharmaceuticals, supplies, and tests [23, 31]. These costs are mainly occurred in health care 
sector, but the costs aroused in non-health-care sectors and patients in seeking and obtaining 
the intervention have been also included in the direct costs. On the other hand, costs aroused 
from patients and informal care givers, outside of the health care sector, are termed indirect 
costs. The definition of ‘indirect’ cost is much more inconsistent across literatures. Production 
loss related to illness or death or time loss of patients and informal care givers mainly related 
to their working time has been involved in indirect costs [1, 23]. The table below shows 
various definitions of the ‘direct’ and ‘indirect’ costs that each author defined based on 
existing literatures and their own interpretation.  
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Table 2. Definition of direct and indirect cost 
Source Direct Cost Indirect Cost 
Luce and  
Elixhauser   
(1990) 
[32]
 
Actual changes in resource use 
attributable to the medical technologies 
under scrutiny 
The economic value of any 
consequence that cannot be counted as 
a direct cost. 
Weinstein 
(1990)
[33]
 
Costs and savings to the health care 
delivery system, personal costs to 
individuals directly related to the 
implementation 
of a program, and non-health economic 
costs and savings 
Changes in the productive use of time 
by patients and others 
Gold et al. 
(1996)  
Changes in resources use attributable to 
the intervention or treatment regimen 
Productivity gains or losses related to 
illness or death 
Drummond et 
al. (2005) 
Resources in the health care sector, 
patient’s out of pocket expenses, 
resources from other statutory agencies 
and voluntary bodies 
Time loss of patients and informal care 
givers mainly/ 
Production gains or losses. 
Elliott and 
Payne           
(2005) 
[34]
 
Costs incurred by the health services 
classified into medical costs (staff time, 
medical supplies, hotel cost, capital costs, 
overhead costs) and non-medical costs 
(patient’s out of pocket money and costs 
occurred in other part of societies) 
Costs incurred by reduced productivity 
of a patient and their family, resulting 
from illness, death, or treatment. 
Olsen     
(2009) 
[26]
  
Costs incurred in health care Costs incurred in other sectors, most 
notably the production consequences 
for the rest of economy 
 
Due to the lack of consensus on a definition of ‘direct’ and ‘indirect’ cost, since mid-1990s 
there has been a tendency towards more detailed sub-classification to avoid confusion aroused 
from dichotomous cost classification [1, 23]. In order to avoid confusion, Gold and co- 
workers (1996) re-defines ‘direct cost’ in a broader term including certain time and 
productivity cost and renamed other costs which have been termed indirect costs. Drummond 
(2005) subdivides costs into 4 categories depending on the area where the costs were incurred: 
health care sector, other sector, family/patient and productivity losses [1]. Johnston and co-
workers (1999) also review existing cost classifications and divides costs into 4 categories: 
direct health care costs, direct non-health-care costs, indirect health care costs (future costs), 
indirect non-health-care costs throughout a review of existing cost classifications [25].  
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Table 3. Sub-classification of costs by different authors 
Source Sub-classification of costs 
Gold et al. 
(1996) 
- Direct health care costs: the costs of tests, drugs, supplies, health care personnel,  
   and medical facilities 
- Direct non-health-care costs: informal care giver time cost, child care costs 
- Patient time costs: travel and waiting time 
- Productivity costs (morbidity costs, mortality costs): costs associated with lost or 
   impaired ability to work or to engage in leisure 
Johnston et 
al. (1999)
[25]
 
- Direct health care costs: hospital care, drug use, etc. 
- Direct non-health-care costs: patient travel costs, etc. 
- Indirect health care costs: costs of health care consumption during added  
  life years 
- Indirect non-health-care costs: The value of production loss due to illness  
  or treatment; the opportunity cost of time spent 
Drummond 
et al. (2005) 
- Health care sector : costs in operating the health intervention 
- Other sector : voluntary or public agencies 
- Family/patient : out-of-pocket money, traveling expenses, expenditures in 
   home, time for seeking and receiving treatment   
- Productivity changes for the treatment, morbidity and mortality 
 
Table 3 shows sub-classification of costs by different authors. If ‘direct’ and ‘indirect’ term is 
ignored, costs can be classified into two categories: health care costs and non-health-care 
costs. Health care costs involve all costs for medical services and future health care costs in 
added life years resulting from a health intervention. Resources consumed to produce health 
services, pharmaceuticals, equipment and facilities, and tests in providing hospital care and 
community care are referred to health care costs [31]. Thus, the quantities of bed days, 
overheads, general practitioner or nurse visits, use of ambulance needs to be counted for 
estimating costs. The costs for treating side effects and additional health care cost occurred 
during extended life years as a consequence of health intervention is also included in this 
category as well.  
Gold and co-workers (1995) contents that the ‘non-health-care costs’ is a term including 
transportation costs consumed in commuting to clinics or hospitals, as well as child care costs 
if parents need to be away from their children for receiving treatment. Non-health-care costs 
are mostly occurred in other sectors such as social services, patients and family members. 
Importantly, the costs paid by other entities of society such as voluntary bodies and patients 
themselves as a form of out of pocket money in relation to health care services are not 
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included in non-health-care cost category. Among them, this study focuses mainly on 3 types 
of non-health-care costs which have important implications in screening: 1) travel costs, 2) 
time costs, and 3) productivity costs.  
1.3.1 Travel Costs 
Travel costs are the traveling expenses for commuting health care facilities such as clinics or 
hospitals. Patients or their company use public transportation, privately owned car or even 
ambulance to commute health care facilities. The amount of money spent in commuting from 
and to the site of care is measured and valued in estimation of travel costs.  
1.3.2 Time Costs 
Because time is uncompensated resources that the patients and unpaid informal care givers 
spent to receive health care, it should be counted in the economic evaluation at its opportunity 
cost [8, 31]. The concept of time cost which is distinguished from productivity costs (indirect 
costs) has been supported by the US panel (“the Washington panel”) [8, 35] . However, the 
distinction is confusing, in that time and productivity cost  is overlapped to some extent [36]. 
The US panel defines time cost as costs of time lost during illness(morbidity time) or while in 
treatment [23].  The cost associated with this morbidity time, however, has been captured in 
productivity costs (indirect costs) when patients or unpaid informal caregivers cannot work 
due to illness.  
For maintaining consistency in use of terms, in this study, time cost mainly refers to the cost 
associated with time loss in treatment. Following the definition, relevant time costs include 
the value of time spent for traveling to a clinical site, waiting and receiving care of patients 
and unpaid informal caregivers. In addition, forgone leisure time during morbidity is also 
included in the time cost, as it is not captured in productivity costs, but it is the real cost to 
patients and informal caregivers.  
In some instances, omission of time costs can lead to a bias in favor of health care 
intervention that relied on patients’ time costs. For example, if one of competing health 
interventions requires more patients’ time- off than the other, a comparison disregarding this 
time cost cannot be reliable. In particular, screening program requires regular day off for 
screening, and thus the costs associated with time loss to individuals are significant compared 
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to other health intervention. The valuation of time costs is inconsistent across guidelines. In 
principle, time should be valued as its opportunity cost. Thus, whether individuals use time 
that they would otherwise have been used for working or leisure, valuation of time cost can be 
differentiated. When valuing time from working hours, wage rate is an acceptable measure of 
its opportunity cost. However, some guidelines do not agree that wage rate properly reflects 
opportunity cost of leisure time. The detailed recommendation concerning valuation of time 
cost would be discussed later.  
1.3.3 Productivity Costs 
The improved health of people as a consequence of treatment can contribute to increasing 
their productivity at work place. On the other hand, illness reduces the productivity of labour. 
Productivity loss is the real cost aroused from health intervention and not transferred from one 
to another entity in the society. Thus, relevant ‘productivity change’ due to the morbidity and 
pre-mature death needs to be taken account in capturing full impact of health intervention. In 
some occasion, these costs are called morbidity cost and mortality costs respectively [23].  
There is no agreed definition of productivity cost [9]. Gold (1996) defines the productivity 
cost as “the cost aroused from person’s impaired ability to work due to the illness or 
premature death from that illness”[23]. On the other hand, Hunink (2001) describes it as “the 
societal value of time spent for sickness or lost due to early death”[31]. In this thesis, 
productivity cost is defined as costs incurred by lost or impaired ability to work due to illness, 
disability and pre mature death. Based on the definitions, relevant productivity costs which 
can be included in the economic evaluation are, 1) productivity change by patients and 
informal care giver from morbidity, mortality, averted illness, and 2) lost productivity while 
on the job.  
In a competitive market, market price can be a good proxy to value items, but there is no 
available market price corresponding to improvement in productivity. As an alternative, 
human capital approach (HC) and friction cost approach (FC) have measured productivity 
costs. The HC approach has been dominant in valuing time and productivity cost by assigning 
wage rate to value the benefit of health intervention [37]. Reasoning of human capital 
approach is that health care program is an investment to the human capital and the benefit of 
this investment can be measured in terms of the individual’s improved productivity. Its 
additional underlying assumption is that wage rate fully reflects productivity of individuals. 
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The value of wage rate is measured by referring age, sex, occupation and employment rate of 
beneficiaries of health program in question.  
The use of wage rate, however, has been criticized in terms of distributional and ethical 
concern. The opponents to the HC claim that the HC favors the people who are young, white 
and socially active and less considers people who are engaging in unpaid work, unemployed 
or socially vulnerable. Concerning criticism against use of HC, several techniques were 
developed to count productivity cost of people outside of labor market. For example, the wage 
of domestic help is employed to value the productivity cost of people who are mostly engaged 
in housekeeping [32].  
The accuracy of HC has also been questioned by the proponents of the friction cost approach 
(FC) [38-40].  They contend that real production loss is less than the estimates of HC when 
the vacancy as a result of morbidity and mortality can be replaced by others or covered by 
patients themselves when they recover. The proponents of the FC emphasize that the time and 
cost of recovering the reduced production to the initial level is a matter of estimating 
production loss. In that respect, the FC seems more accurate instrument to estimate the real 
time and productivity cost.  However, FC requires more efforts to estimate the accurate cost at 
the employer level.  In order to estimate FC, average job vacancy duration which is varied by 
many factors such as market, employer, and employee is necessary to estimate the real cost to 
the society [9]. Because of the practical problem and lack of theoretical ground, the use of FC 
in economic evaluations is still limited. 
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1.4 Guidelines for Economic Evaluation 
The guidelines of economic evaluation have methodological disparities over how to treat  
time cost and productivity cost [7]. Lack of standardization of guideline limits appropriate 
comparison between health care programs which is the source of decision making in resource 
allocation. This section overviews varied recommendations of guidelines concerning non-
health-care costs and make comparison between them.  
1.4.1 US Panel Approach [8, 23, 35, 41, 42] 
The US Public Health Service (PHS) convened a project to develop consensus based 
recommendations for Cost Effectiveness Analysis in 1993. The Panel on Cost Effectiveness 
in Health and Medicine, so called US panel, attended to the project aiming at publishing 
methodological guidelines of CEA which comprised of three articles in a row.  
The US panel proposed use of standard set of methodological practices (reference case) and 
societal perspective in order to keep consistency in the accounting of costs and consequences. 
The societal perspective is most comprehensive in capturing all costs and benefits regardless 
of to whom it was accrued [1, 8, 23]. Therefore, all costs on the whole society should be 
incorporated either in the numerator or the denominator of C/E ratio. US panel listed costs 
components which should be listed in a numerator of C/E ratio as follows: costs of health care 
services, costs of patient time expended for the intervention, costs associated with care giving 
(paid or unpaid), other costs associated with illness, such as travel expenses, economic costs 
borne by the rest of society (including employers) and friction costs due to absenteeism and 
costs associated, etc.  
With respect to non-health-care costs, the US panel distinguishes time cost from other 
productivity costs. Based on its identification, if the reason for absence from work place is 
treatment, the amount of production loss is counted as time cost. They contend that time spent 
by individuals seeking and receiving intervention can be seen as a component of intervention, 
and therefore this time loss should be valued in monetary terms and incorporated into the 
numerator of C/E ratio. However, the US panel recommends that productivity cost needs to be 
incorporated on the denominator of C/E ratio. The panel contended that monetary value for 
lost life years should not be included in the numerator due to double counting problem. The 
panel assumed that the effects of morbidity on productive time and leisure are captured by 
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QALY. They saw that respondents take into account their lost income and reduced 
productivity when they are asked to measure the utility of given health state.  
This recommendation, however, led to a heated debate [8, 35, 43]. The debate started from the 
different point of view on whether the productivity loss should be considered costs or effects. 
In response to the opposition, US panel subdivides the productivity cost to three groups 
depending on the subject of being influenced: 1) individual 2) employers and 3) society [35]. 
The US Panel agrees that the productivity cost to the employers and the rest of society needs 
to be included in the numerator. When people get ill, the employer may have to pay additional 
money to compensate the production loss by recruiting and training new people. This could 
be seen as productivity cost accrued to the employers. The reduced productivity and income 
of individuals also have influence on the amount of income taxes and consumptions of other 
members of society. This is the social cost that other part of society needs to bear. However, 
the US panel does not amend their initial recommendation that the productivity cost to the 
individuals needs to be placed on the numerator. They saw that the income loss to the 
individual is captured by the denominator.  
In terms of measurement of non-health-care costs, the US panel recommends valuing spent 
resources at its opportunity cost. However, in case of non- market items such as time or 
productivity, direct measurement of opportunity costs is impossible. Productivity costs for 
working people, therefore, needs to be valued by gross income corresponding to their age and 
gender. The opportunity cost of individuals who are mostly engaged in leisure such as retirees 
also can be measured by average wage of labor in similar age and gender. The panel also state 
that the friction cost can be used to measure the costs that employers and the rest of society 
need to bear until the lost productivity is recovered.  
1.4.2 Erasmus Group Approach [38, 39, 43-46] 
With regards to the guideline of US panel, Brouwer (1997) commented that they could not 
agree with US panel’s method on incorporation of time and productivity costs [43]. Because 
the group of authors is from Erasmus University in Netherlands, these authors are called 
‘Erasmus group’ in general. They gain attention for proposition of ‘friction cost’ approach to 
value productivity loss.   
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The most distinctive disagreement between the US panel and Erasmus group is on whether 
the productivity loss to individuals needs to be regarded as costs or effects. Erasmus group 
defines productivity costs as costs associated with production loss and replacement costs due 
to illness, disability, and death of productive persons, both paid and unpaid [43]. They have 
emphasized to include both time costs as well as productivity costs to the numerator of the 
C/E ratio. They argued that incorporation of productivity costs as health effects in the 
denominator is not correct and only effects on quality of life that cannot be valued in 
monetary term needs to be include in denominator as  health effects [43]. They claim that the 
recommendation of US panel does not give an accurate estimation of real productivity cost to 
the society because productivity cost is not included when measuring health related quality of 
life. They emphasized that most of questionnaires measuring health related quality of life do 
not contain income factor and individuals do not consider it as much as the US panel expects.  
The Erasmus group also raises the potentials of misrepresentation of individual productivity 
costs. This is because when respondents are asked to incorporate income effect to valuing the 
health related quality of life, they are more likely to take into account social benefits as well 
as private insurance. This tendency could result in more variability of responses across 
countries having different social security system. However, this is an empirical question and  
more researches on the respondents’ consideration when measuring preference of health state 
needs to be addressed [6].  
Erasmus group sees that time and productivity loss due to treatment, morbidity and mortality 
can be measured in terms of monetary terms.  The ‘friction cost’ method proposed by 
Erasmus group estimate production loss at the company level. They assume that real 
productivity loss depends on the friction time that the work loss due to illness, morbidity and 
mortality becomes recovered to the original level. The friction cost method needs more 
information on the average duration of absenteeism and its costing method to determine 
productivity loss. The length of absence is associated with the employee, the employer, or the 
market and therefore there needs more detailed data to estimate the average length of job 
vacancy varied by age, sex, occupation and etc. The value of lost productivity is on the other 
hand determined by internal labor reserve and productivity of people who make up the lost 
work; their valuation needs more researches.  
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Concerning changes in individual ability of leisure due to illness and intervention, Erasmus 
group contended that it can be captured in QALY as an effect and did not give more detailed 
explanation about the value of lost leisure.  
1.4.3 Norwegian Guideline [47] 
Norwegian Medicines Agency (NOMA) is an authority to assess whether drug expenses for 
treatment should be reimbursed in the National Insurance scheme. A recently revised 
guideline of NOMA in 2012 presents some updated recommendations and requirements of 
economic evaluations when pharmaceutical companies submitting reimbursement 
applications. The Norwegian guideline prefers CUA from a societal perspective. In terms of 
costing, the guideline recommends including all source of resources spent in the provision of 
the health intervention in question. Identification and valuation of these costs needs to be 
performed a head of comparison between alternative health interventions. The market price 
should be used to value unit cost of resources consumed, but VAT is excluded since it is 
transfer payment from societal perspective.  
With regard to time cost, the Norwegian guideline contends that if one of health interventions 
being compared particularly requires more time, this cost should be included and reported 
both with and without inclusion of time costs into estimation. The Norwegian guideline 
specifies two methods in measuring time costs which is varied by the source of time. If time is 
extracted from working hours, average hourly wage should be attached to value the lost time. 
The hourly wage includes income tax and employer’s shares of social payments. If time use is 
extracted from leisure time, the average hourly wage after tax is used to value its time cost. 
This cost is applied to all people regardless of age or employment situation.  
The Norwegian guideline acknowledges that methods of dealing with productivity effect are 
controversial so that it leaves a decision of inclusion to researchers. Inclusion of productivity 
gains and loss is, therefore, not mandatory; individual researchers can choose any of 
estimation method as long as they provide with reasonable justification for their choice. Based 
on the guideline, the time horizon of analyses should be long enough to capture all differences 
between interventions. Net deadweight cost due to tax funding of treatment should also be 
excluded. Except these costs, all costs related to the intervention medicine needs to be 
included in the analysis.  
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1.4.4 Other Guidelines 
WHO guideline [48] 
WHO guideline has tendency to capture costs and consequences of health intervention in the 
social welfare framework. The WHO acknowledges that time and productivity loss should be 
accounted for the economic evaluation, in particular “where they are likely to be substantial”, 
but it suggests reporting them separately from the main outcomes.  
In valuation of time and productivity, the guideline recommends that time cost should be 
valued in terms of the change in welfare. Thus, ideally, the time should be weighted according 
to the individual’s impact on the production of society and the subjects of consumption 
externalities. Concerning productivity loss, the WHO guideline basically agrees that 
productivity costs or gains influencing the consumption of goods and services should be 
included as well, but it acknowledges that wage rate does not fully reflect changes in 
productivity. Furthermore, the WHO does not agree with the assumption of the US panel that 
utility weights for QALY capture the productivity loss to individuals.  
UK guideline [49] 
In 2013, the UK National Institute for Health and Care Excellence (NICE) published the 
newest version of guideline for health technology appraisal. The guidance is provided to the 
National Health Services (NHS) England for publicly funded health program. The NHS 
guideline presents a reference case that researchers refer to and it contains recommendation 
that only costs relevant to the NHS and Personal Social Services (PSS) needs to be included.  
Concerning time and productivity cost, the informal care giver’s time cost should be included 
but presented separately. The NHS acknowledges the different valuation methods and gives a 
choice to individual researchers. Individual researchers instead are required to justify their 
choices and perform sensitivity analysis due to its uncertainty. With regards to the 
productivity cost, the guideline recommends excluding it since this cost is not relevant from 
the perspective of NHS and PSS. 
 
21 
 
1.5 Aims of Study  
Against the background of variation in guidelines with regards to the inclusion of non-health-
care costs, this study aims to explore to what extent non-health-care costs are considered in 
economic evaluations. This study does not answer the normative question on how relevant 
costs should be included and estimated. Instead, it dedicates more on the current practice of 
individual researchers; how much researchers have varied interpretations about the non-
health-care cost in terms of identification, estimation and incorporation will be focused on.  
The study, therefore, mainly deals with questions below:  
 Whether non-health-care costs are included,  
 What types of non-health-care costs are included  
 If it does, how they are measured.  
A systemic review of cervical screening studies could be a good case study to answer these 
questions. Identification of non-health-care costs in cervical cancer screening studies is 
expected 1) to understand the current practices of costing non-health-care resources consumed, 
2) to find better way of capturing full range of costs associated with intervention, and 3) to 
give insight to improve the consistency of the methodology used in economic evaluation 
analyses. 
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2 METHODS 
A systemic literature search of Pubmed, Embase and Cochrane library up to 19 February 2014 
was conducted to identify economic evaluations of cervical cancer screening. The following 
terms were used for searching: “cervix”, “screening” or “test”, “cost” or “cost effective” or 
“cost utility”, “economic evaluation” or “analysis” and “cancer”. There were neither language 
nor publication types restrictions in primary searching.  
The full search strategy for each data base is as below:  
 
 Pubmed, N=561 
(cervi*[title]) AND (screening [All Fields] OR test [All Fields]) AND 
(cost[title/abstract] OR costs[title/abstract] OR cost-effective*[ title/abstract] OR cost-
utility*[ title/abstract]) AND (analysis[All Fields] OR economic evaluation[All Fields]) 
AND cancer 
 
 Embase, N=646 
(cervi*).ti. and (screen* or test ).af. and (cost-effective* or cost-utility*).af. and 
(analysis or economic evaluation).af. and cancer.af.  
 
 Cochrane library, N=79 
(cervi*) AND (screening OR test) AND (cost OR costs OR cost-effective*OR cost-
utility*) AND (cancer) AND (analysis OR “economic evaluation*”)  
Study Selection 
A primary interest of the study is a practice of costing non-health-care resources consumed. 
Thus, full economic evaluations of cervical cancer screening were selected for a case. Articles, 
which did not satisfy the requirements of full economic evaluations or its main intervention is 
not a cervical screening, were excluded. This means that cost analyses and cost-of-illness 
analyses were excluded. Articles providing too limited information of costs that it is not 
available to study what kinds of costs were included were also excluded.  
Inclusion Criteria 
In order to be included in the systematic review, the article should have the following 
attributes: 
 Original research paper (reviews, conference abstracts were excluded) 
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 Full economic evaluations (cost analysis or article with no comparison were excluded) 
 Articles in English 
 Articles with available full texts on the internet 
 A study compares both costs and effects of at least two health interventions (including 
no-screening intervention) 
 At least one of interventions is ‘cervical screening’    
Exclusion Criteria 
Articles contain one of those attributes were excluded from the analysis 
 Articles which is not available to define which costs were included 
 Articles which do not present costs and effects in a conventional unit 
(ex. Cost saving per life year lost, DALY lost)  
Initially, 1286 potentially relevant articles were identified from 3 electronic databases 
(searched 12.Feb.2014). Excluding duplicates and triplicates (N=389) resulted in 897 unique 
publications. Throughout screening the titles of the articles, 653 were excluded because the 
title indicated that the publication was not relevant. Of the 244 articles reviewed in abstracts, 
139 publications were excluded based on predefined inclusion and exclusion criteria. For the 
remaining 105 papers, the full paper was scrutinized, and 23 were excluded based on the same 
inclusion/exclusion criteria above. Among those excluded, 15 articles were not relevant to the 
subject of study; three articles were excluded due to the language limitation, and one article 
was not an original research paper. Four articles were excluded for the following reason: an 
article presented its outcome in cost saving per life year lost [50], provided too little or 
inaccessible information to identify what kinds of costs were included [51, 52] and applied 
varying cost inclusion criteria to each intervention [53]. As a result of screening, total 82 
articles were finally selected.  
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Not original research paper 
(N=42) 
Irreverent subjects (N=10) 
Articles Included 
N= 85 
Not full-evaluations (N=3) 
Irreverent subjects (N=15) 
Not original research paper (N=1) 
Not applicable (N=4) 
-  Unconventional outcome unit 
-  Too little information 
-  Applied varying criteria 
 
Figure 2. Study selection flow diagram for economic evaluations of cervical cancer screening 
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Data extraction  
To search the degree of concerning non-health-care resources in the economic evaluation, 
following data were extracted from all original papers.  
 Lead author 
 Year of publication 
 Source of publication 
 Types of study 
 Main interventions (defined by a study question that authors mainly addressed)  
 Country of the study 
 Perspective of the study 
 Cost classification 
 Cost inclusion 
 Discounting 
 Currency, base year 
The data below were additionally extracted only from the articles (n=49) reported non-health-
care costs.  
 Types of non-health-care costs included 
 Method of estimation 
 The proportion of non-health-care costs 
 Incremental Cost Effectiveness Ratio 
 Sensitivity Analysis 
Supplementary readings were referred when information is not available in the main article. 
Extracted data were processed to reach a consistent data base for the review. 
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3 RESULTS 
The systematic research yielded 82 economic evaluations of cervical cancer screening from 
42 different journals. Characteristics of included articles are described first, and study results 
concerning non-health-care costs would be provided in the latter part.  
3.1 Characteristics of the Studies 
Year of publication 
The earliest economic evaluation study available on the Internet was one published in 1985 
[54]. Even if there were some articles published in 1972, these articles were not available on 
the Internet, and therefore were excluded from the review. As shown in Figure 3, there was a 
time trend of the number of studies as well as the subjects of the studies.  
Figure 3. The included studies according to publication year 
 
Only few studies were published in the mid-1980s to 1990s. The earlier publications during 
this period were mostly about the effectiveness of Pap screening in a country where national 
cervical cancer screening was implemented. Most of these studies compared pap screening 
with no screening or changed in intervals of screening in order to find the most cost effective 
screening strategy. Form the late 1990s to early 2000s, the number of publications slightly 
increased and the subjects of screening studies became varied; different types of screening 
including Human Papilloma Virus (HPV) test, Liquid Based Cytology (LBC) and visual 
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inspection with acetic acid (VIA) were examined. Since the late 2000s, the number of articles 
has increased again. These articles mainly focused on the cost effectiveness of various types 
of screening tests in combination with HPV.  
Types of economic evaluation 
When outcomes were presented in life years saved (LYS) or numbers of detected cases, the 
studies were classified as cost effectiveness analysis (CEA). Studies, which presented one of 
its outcomes in QALYs or DALYs, were classified as cost utility analysis (CUA).  
The total number of CEA was 44, among which 38 articles reported its effects in terms of 
LYS, and the rest of six articles used numbers of case detected/averted to express its effects. 
The number of CUA was 37, among which 24 articles presented its effects in terms of QALY, 
while 11 articles presented its effects both in LYS and QALY. Two articles of the same lead 
author used DALY averted as the unit of benefit. There was only one cost benefit analysis 
(CBA) which presented its outcome in terms of a cost benefit ratio. 
Figure 4. Types of economic evaluation 
 
Types of interventions 
The included studies explored cost-effectiveness of various screening strategies or 
combination of screening and vaccination. 36 studies (44% of all) examined the cost- 
effectiveness of different types of cervical screening test (Pap, LBC and HPV test). Among 
them, 25  investigated the feasibility of adding HPV triage to the conventional cytology 
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screening (Pap or LBC) while 11 studied which types of test is the most cost effective when it 
is implemented in a limited resource setting . There were 30 (36%) studies, which explored 
the cost-effectiveness of screening in combination with HPV vaccine. Nine (11%) studies 
compared different intervals of screening. Three (4%) studies explored the feasibility of 
introducing HPV test using self-collected specimens. Additionally, there were four other 
studies; those articles were on management alternatives for women with low grade 
abnormalities [55], comparison of same type of screening provided by different health care 
facilities [54], cost effectiveness of adding speculoscopy into conventional Pap screening [56] 
and cost effectiveness of cervical screening in a emergency room at the public hospital [57].  
Figure 5. Interventions of the studies  
 
Country of study 
There were 8 multi-regional studies and 74 country level studies. Multi regional studies 
covered screening policies of different countries. The most extensive study in terms of region 
was the cost effectiveness of cervical cancer screening in a global perspective [58]. Two of 
multi-regional studies were about different screening policies of European Union (EU), while 
rests of them studied countries with limited resource settings.  
Figure 5 provides the number of publications in terms of the country as a result of analyzing 
74 country level studies. 28 countries were subjects of the studies, and 10 studies did not 
match the country of study and the place where it was conducted. The United States was the 
most often studied (N=16), followed by the Netherlands (N=7), Canada (N=6), the United 
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Kingdom (N=5), Japan (N=4) and China (N=4, including Taiwan). According to the country 
classification of World Bank, the number of studies investigated the middle income countries 
were 10, those studies explored high income countries was 17 and there was one study 
investigated low-middle income country. 
Figure 6. Country of the study 
 
Study population 
Unlike most studies which examined general female population, there were 19 studies (23%) 
explored specific population such as women who received abnormal test results from a 
previous screening (N=6) or cervical cancer patients (N=1). Four studies conducted in US 
chose low income, elderly or ethnical minority for a study population [57, 59-61]. The other 
studies investigated a cervical screening of HIV infected women (N=3), women in military 
services (N=2), kidney transplants (N=1) and pregnant women (N=1).  
Discounting 
Discounting is a technique to put costs and benefits occurred in the different time points on 
the same base [62]. Cost effectiveness studies of prevention program are known to be 
sensitive to the discounting rate because many of the benefits from the cervical screening 
occur in the future. Based on the result, 92% of studies (N=76) discounted the future costs and 
benefits (extended life years or QALY). The discount rate was 3-7% varied between the 
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studies. Among the studies, the discount rate of 3% was the most preferred (71% of studies) 
followed by 5%. Five studies applied differential discounting to costs and benefits 
respectively: Canadian and Australian study (5%, 3%), Belgian (3%, 1.5%) and Netherland 
(4%, 1.5%). Two studies applied three different discount rates to both costs and effects in 
consideration of the impact of discounting on the cost effectiveness [63, 64].   
Figure 7. Discount rate 
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3.2 Non-Health-Care Costs of Cervical Cancer 
Screening 
Despite of the relative importance of non-health-care costs in screening program, only 40 
(49%) articles included non-health-care costs, and the other 42(51%) articles ignored its 
inclusion. Even among the studies including non-health-care costs, they showed varied 
interpretations about inclusion criteria. The distinction between time and productivity cost 
introduced by the US panel was not properly understood in practices.  
Perspective of the Study 
Explicit and clear specification of the perspective is recommended for clear understanding of 
the analysis [31]. There were 31 (38%) studies adopting a societal perspective. Among them, 
four studies chose double perspectives (societal and non-societal perspectives), and presented 
outcomes for each perspective. One study reported an ‘adjusted’ societal perspective which 
did not account for productivity costs. Among the other 51 studies, which did not choose 
societal perspective, 29 chose a perspective of the health care system. 19 (23%) studies did 
not specify which perspective they chose for the study. It was especially difficult to interpret 
studies with a lack of explicit perspective as to what kind of costs was included in the analysis.  
Two studies chose a perspective of Ministry of health and one chose perspective of 
government in general.   
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Figure 8. Perspective of the studies 
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Nomenclature for classification of costs 
The way of classifying costs into groups differed across studies. A dichotomous taxonomy 
(indirect versus direct costs) was used in 20 (24% of total publications) studies, most of them 
published in the 2000s (N=18). There were 33 (39%) studies, which classified costs into more 
than two categories. The ‘direct medical’ cost was the most preferred term referring to the 
costs incurred in a health care sector. It denotes all components of costs occurred in test, 
specimen transport, laboratory process, staff time, office visit and treatment of cancers 
including treatment for complications and hospitalization. The term ‘health care cost’ was 
also used in the same meaning of ‘direct medical cost’. In terms of non-health-care costs, 
‘Direct non-medical’ or ‘indirect’ costs were often used to refer to the time and travel costs or  
sometimes costs associated with productivity loss due to morbidity and mortality. 29 studies 
did not classify the costs with the conventional criteria. These studies, instead, used individual 
name of costs identified by test/treatment procedure, or progress of disease. One article 
unusually classified the costs by the budgetary authorities (testing, physicians, inpatient, and 
outpatient services) [65].  
In the following, the terms defined on page 12-15 will be used.   
Inclusion of non-health-care costs 
Of the 82 included articles, 40 (49 %) articles included at least one type of non-health-care 
costs (travel, time and productivity costs). Three articles were unavailable for evaluation 
because they did not specify the perspective of the study nor their cost classification. The 
inclusion of non-health-care costs increased over the years. Studies conducted in the 
Netherlands had a high proportion (six out of seven) with inclusion of non-health-care costs.  
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Figure 9. Inclusion of non-health-care costs 
 
The extent of inclusion of non-health-care costs varied even in the studies using the same cost 
classification. Among the 40 articles including non-health-care costs, 37 (93%) included time 
costs, 30 (75%) included travel costs, and 10 (25%) included productivity costs.  It reflected 
that researchers have varied interpretations of cost components needs to be included into non-
health-care costs. Most of articles included time and travel costs only, and very few studies 
took productivity costs into account. Only four articles included all types of non-health-care 
costs, of which three articles were from the same lead author [55, 66-68].  
Figure 10. Inclusion of non-health-care cost components 
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Identification and estimation  
This of the following is a result of the study of 40 articles including at least one type of non-
health-care costs.  
Travel costs 
In published articles, travel cost was defined as a cost for patients to commute to the clinical 
site for a screening, diagnosis and further treatments. Most of studies measured round trip-
transportation to the clinical site made by women being subjects of care with an assumption 
that women used public transportation. Only one study included travel costs of a companion 
[55].  
Measurement and valuation of traveling cost varied. Travel costs were measured by the level 
of health care facilities, or purpose of traveling, whether it was aiming at screening, diagnosis, 
further treatment for detected abnormalities, or treatment for advanced cervical cancer. The 
latter travel cost, for cancer treatments, was much higher than for other types of care. In 
almost all studies, travel expenses for round trip were used to value the travel costs.  Most of 
travel cost data stemmed from the study’s own patient level costing, survey or other 
literatures. The data extracted from other literature were extrapolated using country specific 
data referring to the density of health care facilities, percentage of urban/rural population and 
road infrastructure.  In the cost table provided by the studies, travel costs were reported 
separately or in a combination with time costs.    
Time costs 
Time cost mostly denoted patients time spent for traveling to and from the clinical site, 
waiting, and receiving care. It included all visits of patients in screening, diagnosis, and 
treatment for complications and hospitalization. The variation in time costs was greater for 
travel than for time spent in testing or treatment. Depending on the availability of 
transportation and accessibility to the health care facilities, travel time was varied from 30 to 
230 minutes per episode of screening. In countries with only few health care facilities for 
treating advanced cancers or low population density, travel times were greater. The waiting 
time was also varied from 15 to 90 minutes. As a result, a total time (including 2 way round 
trip, waiting and receiving care) spent per episode of screening was varied from 55 (US) to 
325 (Kenya) minutes. However, even within a studies examining same country (US), the time 
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variation appeared [56, 69].  The time data mostly originated from patient level costing or the 
literature. One study simply applied an assumption made by the authors [56]. 
All studies employed a wage rate to value the time costs which indicates that human capital 
approach is widely accepted. However, each study used different types of wage rates: average 
wage rate (N=7), average gross income adjusted for social benefits (N=1), median wage rate 
(N=3), minimum wage (N=2), salary varying by military rank and adjusted for fringe benefits 
such allowable housing costs (N=1). One study used both average and minimum wage 
varying employment status of women [70]. A number of studies adjusted wage rate for the 
characteristics of the each groups of population which varied by age, income level, a place of 
work (public/private or formal/informal), and employment rate. Unusually, one study valued 
time costs in terms of utilities [71]. This study assumed that the utility of patients is likely to 
decrease due to the anxiety and inconvenience from spending time to care. Reporting of time 
cost also varied by study; some studies measured time spent in traveling, waiting and 
receiving screening separately, while others measured in an aggregated form.  
Productivity costs 
To some extent, the definition of productivity cost used in studies was overlapped with time 
cost. Unlike the time cost which was almost similarly used between the studies, researchers 
had varied interpretations about the productivity cost (mostly referred to production loss or 
indirect costs). In most of guidelines, productivity cost is defined as production loss resulting 
from morbidity and mortality. Some studies, however, defined it as “production loss absence 
from work due to complications and after effect”[55] or the value of time that “a patient is 
either physically incapable of or otherwise unavailable to perform employment related 
activities” [69]. A cost benefit analysis (CBA) defined it as discounted current value for 
future earnings, labor day loss for treatment [54].  
In valuation of productivity costs, assigning wage rate to the value was most commonly used 
(N=5 among 11 studies). However, each study used different types of wage rate: median 
(N=2), average (N=2), salary (N=1).  The time away from work due to illness was not 
specified in the articles. Only, Taylor and co-workers (2000) assumed that it takes 1.6 days 
per year for treating Low-grade Squamous Intraepithelial lesion (LSIL) and High-grade 
Squamous Intraepithelial lesion (HSIL), while cervical cancer requires 35.4 days per year for 
treatment [56].  There were no studies including friction costs into costing. With regards to 
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the incorporation of the productivity costs, three out of ten studies described explicitly that 
productivity costs to the individuals is captured in terms of ‘reduced utilities’ [64, 72, 73].  
Some studies recognized productivity cost as real costs and put them on the numerator of 
ICER [55, 56, 74]. Three studies did not specify the methods in valuing productivity costs 
[66-68].  
The magnitude of non-health-care costs  
There was considerable variation in terms of the proportion of non-health-care costs of total 
screening costs. No study reported all types of non-health-care costs including time, travel, 
and productivity cost. The results in terms of the magnitude of non-health-care costs are, 
therefore, limited to the proportion of time and travel costs to the health care costs. The time 
and travel cost accounted for 0.04-76% of total costs per screening (pap: 0.12-76%, HPV test: 
0.05-42%). In terms of its ratio to the health care costs, two studies reported 0.17: 1 and 
1.47:1 respectively [75, 76].  
It is uncertain whether the proportion of non-health-care costs is greater for the screening 
itself than the subsequent treatment of cervical cancer that is not prevented by the screening. 
The study conducted by Praditsitthikorn and co-workers (2011) demonstrated that the 
proportion of non-health-care costs was greater for the cancer treatment than the screening per 
se [76]. Other studies found that the time and travel costs accounted for 5-48% of cancer 
treatment costs [77, 78].  Here, the ratio of these types of non-health-care costs to health care 
costs was 1: 1.17-4.5 with no discounting (1: 0.2-1.19 with discounting).    
Table 4. Proportion of time and travel costs to health care costs 
 Screening cost Cancer treatment cost 
Proportion of non-health-care costs   
(time and travel) 
0.04-76% 5-48% 
Ratio of non-health-care costs (time and 
travel) to health care costs 
0.2-1.47 : 1 1.17-4.5 : 1 
 
Figure 11 presents the time and travel costs as a percentage of the health care costs in 
screening (costs of the tests, office visits and laboratory costs) excluding cancer treatment 
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costs. The percentage ranged from 18% to 327% (time cost: 5%- 139%, travel cost: 1%-106%) 
of the health care costs per pap screening. Norway reported the biggest estimates (327%) [79], 
while the smallest was reported in Netherlands (18%) [71, 80].  
In the studies which explored HPV test of low and middle income countries, the time and 
travel cost was amounted to 5-324% (time cost: 10 -285 %, travel cost: 0-52%) of the health 
care costs per screening. Due to the geographical disadvantage in rural areas and low 
accessibility to the health care facilities, the time spent for traveling and waiting was the 
largest in Uganda (324%). In five studies, the magnitude of time and travel costs was greater 
than health care costs for screening.  
Figure 11. Time and travel costs as a percentage of health care costs 
 
Impact of non-health-care costs 
Among the 40 studies including non-health-care costs, 19 presented sensitivity analyses of 
costs (screening, diagnosis and treatment of pre-invasive lesions and cancer). Among them, 
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the results of the study. One of studies showed that inclusion/exclusion of non-health-care 
costs would reverse the rankings of the strategies [70]. Goldie and co-workers (2005) 
demonstrated that when they included the productivity costs from cancer treatment, screening 
became cost saving or more cost effective. In their study, countries where non-health-care 
costs accounted for most of screening costs, the incremental cost effectiveness ratio (ICER) 
was, as expected, more sensitive to variation in the non-health-care costs.  
The results of the other five studies were robust, but the ICERs were influenced by the 
inclusion of non-health-care costs. Only three studies were available to estimate the effect of 
inclusion/exclusion of time and travel costs on the ICER [55, 74, 75]. When including them, 
the ICER decreased by 21-41% on average.  
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4 DISCUSSION 
Like other review articles [81-84], this study also revealed that there is considerable variation 
in the guidelines for economic evaluation of health care programs (health interventions) and 
in the identification, measurement and valuation of non-health-care costs in practices. The 
non-health-care costs have tended to be ignored, but our findings indicate non-health-care 
costs may represent a considerable proportion of the total program costs, and omitting them 
will consequently bias the results. 
Strengths and limitations of the study 
To the best of our knowledge, this is the first study to review the costing practices of non-
health-care costs within the context of screening for cervical cancer. Inclusion of non-health-
care costs has been mainly concerned in cost-of-illness studies (COI) [85-89], while relatively 
little concern has been directed to full economic evaluations (CEA/CUA/CBA). This study 
differs from other studies in that it solely focused on non-health-care costs in full economic 
evaluations. By limiting the subject of study to cervical cancer screening, our study focused 
on methodological disparities within studies for a similar condition (ex. population, 
comparator, research question). The systematic way of searching contributed to the finding of 
as many relevant articles as possible. In terms of generalizability, this study has meaningful 
findings concerning inconsistent treatments over the non-health-care costs in the published 
articles. 
This study, however, has several limitations. First, even if there was partial assistance from 
the thesis supervisor, only one person scrutinized all titles, abstracts and contents. As a result, 
individual judgment could have been more involved in the data collection, which may lead to 
selection as well as information bias. Second, due to the limited number of words in most 
published papers, many articles lacked details so that the authors’ original costing may have 
been misinterpreted. In case where authors did not provide any details on how they measured 
and estimated costs, some pieces of information had to be omitted in our analysis. Third, by 
restricting languages only to English, 14 articles were excluded due to the language restriction. 
This may have limited the number of informative studies.  
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Study findings 
Discrepancy between theories and practices 
Our finding demonstrates discrepancies between the theories and practices. Researchers may 
prefer more simple and practical methods instead of theoretically valid ones. In this sense, 
theory seems to be ahead of practice. Non-health-care costs have been ignored in a number of 
studies. Concerning the nomenclature of costs, a number of studies still classify costs into 
direct and indirect costs [55, 56, 66-69, 73, 74, 90, 91], which have been recommended 
against in the literatures. In valuation of productivity and time costs, no study adopted the 
friction cost approach, while human capital approach was still used despite of the theoretical 
and ethical controversies.   
In terms of measurement, time loss from unpaid informal caregivers (ex. family, relatives) 
was not considered. Omission of such cost may underestimate the societal resources 
consumed in treatment of cervical cancer, particularly in a country where public social 
services for ill people are not well established. In such countries, care for seriously ill patients 
is largely dependent on those unpaid informal caregivers so that inclusion of the time or 
productivity cost of unpaid informal care giver would make cervical cancer screening more 
socially favorable.   
Furthermore, loss of leisure due to the patients’ or informal care givers' time spent for 
treatment or during illness was not captured in any of the studies. Theoretically, this time 
which otherwise could have been spent on leisure if a patient were healthy, should have 
counted as opportunity costs of treatment, but it was not reflected in published studies.  
Inconsistency in costing of non-health-care costs  
Our study showed that most of studies included time and travel costs only, and very few 
studies included productivity costs. Because our study distinguished time costs from 
productivity costs, it may be seen that the productivity loss associated with health 
interventions is less considered in included articles. However, such an interpretation is 
partially incorrect as productivity loss to individuals has been captured in time costs.  
Whether the distinction between time and productivity is accurate is a controversial issue, as 
time spent for treatment or during illness may be productive time to the working population. 
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This time has been recognized in relation to the productivity loss, so that it is not easy to 
conceptually distinguish the time cost from productivity cost. With regards to the confusion, 
the US panel comments that time should be understood as real input of individuals to the 
treatment, and therefore it should be counted as real costs, while productivity loss to 
individuals should be counted in lost utilities  [8, 23, 35, 41, 42]. The Erasmus group, 
however, claimed to such argument in that the US panel’s approach does not comply with the 
principles of societal perspective [45].  
In the published articles, different authors showed varied interpretation associated with the 
distinction between time and productivity costs. Among the included studies in our analysis, 
time cost was first included and distinguished from productivity costs in 1999 [64]. The study 
followed the US panel’s recommendation and counted time costs as real costs, while 
productivity costs to individuals were assumed to be lost utilities in the denominator of the 
ICER. However, the study did not describe how they treated productivity costs to the 
employers and society. Some later published studies even omit the descriptions on how they 
dealt with productivity costs to individuals.  
The inconsistency over the valuation of non-health-care costs seems to be country specific. 
Depending on the women’s labor participation rate and industrial structure of the studied 
country, researchers adjusted their valuation of non-health-care costs. For example, in 
developing countries, large proportions of women are unemployed or engaging in work in 
informal sectors. The studies exploring such countries tend to use minimum wage or 
agricultural wage as a proxy for the productivity losses.  For the developed countries, the 
average wage rate is often used with adjustment of the amount of social benefits (allowances 
for sick leave) and high income tax. In a country such as Norway, high income taxes are 
imposed to the working population, and therefore ignorance of the tax effect could affect the 
value of women’s time and productivity costs. 
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Impact of including non-health-care costs 
The magnitude of non-health-care costs and its impact of inclusion varied significantly among 
studies. When including all types of non-health-care costs, the ICER was reduced by 22-41%. 
However, we cannot generalize the statement that inclusion of non-health-care costs 
necessarily reduces ICER.  
The formulation of ICER of cervical cancer screening is as below.  
(Screening costs (∆H + ∆NH) – averted treatment costs (∆H + ∆NH))/ Effect 
∆H: Increase in health care costs,  
∆NH: Increase in non-health-care costs 
Assuming that effect is given, the cost effectiveness of cervical screening is dependent on the 
trade-off between screening costs and averted treatment costs. If non-health-care costs in 
screening are greater than that of treatment costs, ICER can be greater. For example, if health 
intervention requires large amounts of time for traveling, waiting and receiving care as well as 
travel costs, health interventions become less cost-effective. Moreover, if productivity of 
patients is low valued, like in developing countries, so that the intervention do not avert large 
amount of productivity costs, its inclusion may increase ICER.  
The proportion of non-health-care cost in health intervention was country specific. For 
example, the estimation of time cost is a function of wage rate and time for traveling, 
receiving screening and treatment. Relatively greater time costs were reported in the studies 
of Norway and Rwanda. However, main cost driver is different between two countries. In 
case of Norway, the high wage rate drove up the time costs while long traveling time was the 
main cause of increasing time costs in Rwanda. 
Furthermore, it was evident that fewer visits reduced the time and travel cost, but no study 
provided a magnitude of its effect when extending screening intervals. Only one study 
identified that screening costs are increasing less than proportionally with the number of 
examinations [80]. Another study found that when a longer period of time is applied to the 
study, inclusion of non-health-care costs lowers the ICER [74]. This is because greater 
amounts of productivity costs are averted assuming that the effect of treatment (in our study, 
preventive effect) lasts longer.   
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Distributional consequences 
Since monetary value is assigned to the time and productivity of individuals, inclusion of non-
health-care costs will unavoidably have distributional implications. An ethical concern 
surrounding inclusion of non-health-care costs has been raised since it advantages health 
interventions targeting employed people. When including non-health-care costs,  health 
intervention for the people with higher wage rates – ceteris paribus - becomes more 
preferable than those for others. This is because the greater amount of productivity costs is 
saved, the more cost effective the outcome is.  
Our study reconfirms that wage rate is most commonly used in valuation of time and 
productivity in practice (53% of studies including non-health-care costs). Use of wage rates 
has a potential risk to bring current discrimination and inequality problem of market income 
into the decision making in health care. Bidus and co-workers (2006) provided different 
estimates of time costs varied by rank in military service [69]. Based on the estimates, the 
value of time for the women at the highest rank was 250% higher than the lowest. 
Furthermore, time and productivity losses for women in developing countries are more 
underestimated than those from developing countries. Three studies used minimum wage to 
value the time and productivity loss of women in developing countries, which is much lower 
than medium or average wage [70, 92, 93]. Practical limitation can be one of reasons for 
inducing underestimation since it may not be easy to value the time and productivity of 
women doing domestic chores in rural area.    
Discrimination is also appeared when valuing time costs for people having different 
occupations. A study conducted by Goldie and co-workers (2005) varied wage rate by the 
types of employment, whether the women working in informal employment (without secure 
contracts, worker benefits, or social protection) or formal employment [70].  As a result, the 
time cost for the formal employed was greater than the others. Such estimate indicates that 
economic evaluation values more on the time for people who have more money and secured 
job.   
Quality of reporting costs in the economic evaluation 
Even though the study complies with the standardized method, low quality of reporting raises 
a question of validity of the study. Many of studies showed low adherence to the guidelines in 
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presentation of cost data and costing methods. First, the perspective of study needs to be 
stated explicitly, so that the readers clearly identify what kinds of costs are considered into the 
study. However, in our study, 23% of all included articles did not state the perspective of 
study, which makes more difficult to identify included costs. If a study did not use the proper 
nomenclature (ex. direct non-medical, time cost, etc.) either, it becomes difficult to identify 
the included cost components of the analysis. Second, many studies did not state the costing 
methods in an explicit manner so that it was more difficult to identify the methods of 
measurement and valuation of relevant costs. Third, guidelines suggested reporting unit and 
value of cost respectively, but many of studies did not comply with this requirement. It made 
more difficult to identify which value was used to estimate the costs. Fourth, guidelines state 
that researchers should provide further justification concerning their inclusion or exclusion of 
non-health-care costs. However, no study explicitly specified their reason for 
including/excluding such costs.  
Policy recommendation 
Since the dispute between the US panel and Erasmus group in the late 1990s, the 
controversies related to the inclusion of non-health-care costs have not been settled. The 
discussion was an attempt to standardize methods in economic evaluations, but there was no 
visible improvement in this area since then. In this context, our study empirically indicates 
that it is still room for improvement in defining, estimating and incorporating non-health-care 
costs.  
For the improvement, the development of standardized form is one of solutions. Here, major 
journal could play an important role in leading theoretical discussion for standardization, and 
ensuring the high standards of reporting by calling for more adherences to the standardized 
form when publishing the studies. The journals need to put an effort to develop agreed 
definition of costs and its measurement; these should be specified and detailed enough to 
apply to different study setting (country, disease, health intervention and population 
examined). They should mandate researchers to provide clear description of included costs 
and justification of researcher’s determination. Unclear language in guidelines may lead to 
varied interpretations of researchers. Therefore, more specified guideline is required to reduce 
inconsistency which appeared in costing methods. Most of all, more research on 
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inconsistencies within economic evaluations would contribute to developing theoretically 
correct and practically applicable guideline. 
Concerning distributional implication in valuation of time and productivity, researchers are in 
dilemma between their responsibility to reflect economic reality and the desire to support 
equitable resource allocation. It is inevitable to include ‘productivity’ of patients since it is 
fact that health intervention improves individual life as well as their working ability. 
Therefore, time and productivity cost need to be separately reported so that the decision 
would be left to the decision makers and the society.  
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5 CONCLUSION 
In 1992, Jefferson stated, “there is a long way to go before economic evaluations can be 
regarded as good enough to justify their use in decision making”[94]. Even though many 
attempts have been made to standardize methods as well as reporting, the findings of this 
study indicate that Jefferson still may have a point. To resolve the issue, we need to look back 
to the basic principles of economic evaluations. Definition of certain terms needs to be 
clarified; inconsistency in costing methods should be avoided; standardized costing methods 
should be discussed in consideration of distributional concern. Furthermore, researchers 
themselves should be aware of the possible implications of the analytic choices they made. As 
long as uncertainty associated with impact of inclusion/exclusion of non-health-care costs 
remains, researchers should report non-health-care costs separately so as to ensure the 
transparency of the study. Above all, an attempt to standardize and to justify the methods we 
use in the analysis need to be prioritized in order to keep transparency and comparability 
across studies.  
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